Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2026)
Summit Therapeutics' (SMMT) quarterly Other Non-Current Assets came in at $8.4 million in Q2 2026, up 29.65% YoY from $6.5 million in Q2 2025, and up 2.64% on a QoQ basis from $8.2 million in Q1 2026.
Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of Other Non-Current Assets data on file, last reported at $8.4 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 29.65% year-over-year to $8.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.4 million (up 29.65% YoY) and the FY2025 annual result came in at $7.2 million, up 182.77% from the prior year.
- Other Non-Current Assets climbed to $8.4 million in Q2 2026, from $8.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $8.4 million in Q2 2026 to a low of $140000.0 in Q3 2022.
- A 5-year average of $3.3 million and a median of $2.2 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 2994.29% — and 2024, when it slumped 56.99%.
- Tracing SMMT's Other Non-Current Assets over 5 years: stood at $577000.0 in 2022, then jumped by 649.05% to $4.3 million in 2023, then tumbled by 41.05% to $2.5 million in 2024, then jumped by 182.77% to $7.2 million in 2025, then increased by 17.25% to $8.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $8.4 million (Q2 2026), $8.2 million (Q1 2026), and $7.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 8.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.45 Mn |
| Mar 31, 2026 | 8.23 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Sep 30, 2025 | 7.03 Mn |
| Jun 30, 2025 | 6.52 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 2.55 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 1.88 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 4.33 Mn |
| Jun 30, 2023 | 254,000.00 |
| Mar 31, 2023 | 156,000.00 |
| Dec 31, 2022 | 577,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 179,000.00 |
| Mar 31, 2022 | 166,000.00 |
| Dec 31, 2021 | 170,000.00 |